Literature DB >> 15613460

Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway.

C Péqueux1, B P Keegan, M-T Hagelstein, V Geenen, J-J Legros, W G North.   

Abstract

Malignant growth of small-cell lung carcinoma is promoted by various neuroendocrine autocrine/paracrine loops. Therefore, to interfere with this mitogenic process, it is crucial to elucidate the mechanisms involved. It is known that the oxytocin (OT) and vasopressin (VP) genes, normally transcriptionally restricted in their expression, are activated in small-cell lung cancer (SCLC), concomitantly with expression of their receptors (OTR, V1aR, V1bR/V3R and V2R). The aim of the present study was to characterize, in concentrations close to physiological and pharmacological conditions, intracellular signalling events triggered by OT and VP binding to their specific receptors in SCLC cells and to identify factors mediating OT- and VP-induced mitogenic effects on SCLC. Known agonists for OTR ([Thr4,Gly7]OT) and V1aR (F180), in addition to OT and VP, were able to elicit increases in cytosolic Ca2+ levels and this effect could be blocked using an OTR antagonist (OVTA) or a V1aR antagonist (SR49059) respectively. There was no activation of the cAMP pathway detected after VP, dDAVP (a V2R agonist), or OT treatment. Stimulation of SCLC cells with OT and VP led to an increase of extracellular signal-regulated kinase (ERK) 1/2 phosphorylation, maximal at 5 min, and the subsequent phosphorylation of its downstream target p90 ribosomal S6 kinase (p90RSK). Pre-incubation with OVTA and SR49059, and with inhibitors of phospholipase C (PLC), protein kinase C (PKC), mitogen-activated protein kinase/ERK kinase (MEK) 1/2 and a Ca2+ chelator significantly reduced OT- and VP-induced ERK1/2 phosphorylations. OVTA, SR49059 as well as MEK1/2 and PKC inhibitors also downregulated OT- and VP-induced p90RSK phosphorylation. In [3H]thymidine-uptake experiments, we subsequently observed that PLC, Ca2+, PKC and ERK1/2 are absolutely required for the OT- and VP-stimulated SCLC cellular growth process. In conclusion, the results presented here indicate that OT- and VP-induced mitogenic effects on SCLC are respectively mediated by OTR and V1aR signalling and that this mitogenic signalling passes through the phosphorylation of ERK1/2 and p90RSK in a PLC-, Ca2+-, PKC- and MEK1/2-dependent pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15613460     DOI: 10.1677/erc.1.00803

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  21 in total

1.  The effect of vasopressin on the Zajdela hepatocellular carcinoma growth rate.

Authors:  I I Khegai; V I Mel'nikova; N A Popova; L A Zakharova; L N Ivanova
Journal:  Dokl Biol Sci       Date:  2014-08-30

2.  MICRORNA-AUGMENTED PATHWAYS (mirAP) AND THEIR APPLICATIONS TO PATHWAY ANALYSIS AND DISEASE SUBTYPING.

Authors:  Diana Diaz; Michele Donato; Tin Nguyen; Sorin Draghici
Journal:  Pac Symp Biocomput       Date:  2017

3.  Oxytocin and oxytocin receptor alterations, decreased survival, and increased chemoresistance in patients with pancreatic cancer.

Authors:  Trisheena Harricharran; Olorunseun O Ogunwobi
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2019-12-14

Review 4.  Impact of stress on cancer metastasis.

Authors:  Myrthala Moreno-Smith; Susan K Lutgendorf; Anil K Sood
Journal:  Future Oncol       Date:  2010-12       Impact factor: 3.404

5.  Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.

Authors:  Nicholas G Paciaroni; Verrill M Norwood; Ranjala Ratnayake; Hendrik Luesch; Robert W Huigens
Journal:  Bioorg Med Chem       Date:  2020-05-07       Impact factor: 3.641

6.  Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments.

Authors:  Moulay D Rochdi; Gabriel A Vargas; Eric Carpentier; Geneviève Oligny-Longpré; Stanford Chen; Abraham Kovoor; Stephen E Gitelman; Stephen M Rosenthal; Mark von Zastrow; Michel Bouvier
Journal:  Mol Pharmacol       Date:  2010-02-16       Impact factor: 4.436

7.  Oxytocin induces the migration of prostate cancer cells: involvement of the Gi-coupled signaling pathway.

Authors:  Miao Zhong; Maryam L Boseman; Ana C Millena; Shafiq A Khan
Journal:  Mol Cancer Res       Date:  2010-07-27       Impact factor: 5.852

Review 8.  Neuroendocrine influences on cancer biology.

Authors:  Premal H Thaker; Anil K Sood
Journal:  Semin Cancer Biol       Date:  2007-12-08       Impact factor: 15.707

Review 9.  Is the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC?

Authors:  Sandra Cristea; Julien Sage
Journal:  J Thorac Oncol       Date:  2016-04-29       Impact factor: 15.609

Review 10.  The influence of bio-behavioural factors on tumour biology: pathways and mechanisms.

Authors:  Michael H Antoni; Susan K Lutgendorf; Steven W Cole; Firdaus S Dhabhar; Sandra E Sephton; Paige Green McDonald; Michael Stefanek; Anil K Sood
Journal:  Nat Rev Cancer       Date:  2006-03       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.